Pharmacological basis of different targets for the treatment of atherosclerosis. (Q36346487)

PubMed publication ID

13 August 2017

1 reference

title

Pharmacological basis of different targets for the treatment of atherosclerosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6740287&resulttype=core&format=json

12 May 2020

1 reference

Harjot K Saini

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6740287&resulttype=core&format=json

12 May 2020

Yan-Jun Xu

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6740287&resulttype=core&format=json

12 May 2020

Amarjit S Arneja

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6740287&resulttype=core&format=json

12 May 2020

Paramjit S Tappia

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6740287&resulttype=core&format=json

12 May 2020

Naranjan S Dhalla

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6740287&resulttype=core&format=json

12 May 2020

publication date

1 October 2005

1 reference

PubMed publication ID

16364193

Journal of Cellular and Molecular Medicine

13 August 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6740287&resulttype=core&format=json

12 May 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6740287&resulttype=core&format=json

12 May 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6740287&resulttype=core&format=json

12 May 2020

page(s)

818-839

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6740287&resulttype=core&format=json

Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study

12 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

A survey of 246 suggested coronary risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Statin therapy: where are we? Where do we go next?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Alternative approaches to cholesterol-lowering therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Pharmacoeconomics of lipid-lowering agents for primary and secondary prevention of coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Beyond lipid lowering: the role of statins in vascular protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Atherosclerosis — An Inflammatory Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Cardiac systolic and diastolic dysfunction after a cholesterol-rich diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

The role of oxidized lipoproteins in atherogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Are we aggressive enough in lowering cholesterol?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Lipid management with statins. The lower the better?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Comparative effects of lipid-lowering therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Peroxisome proliferator-activated receptor-alpha and atherosclerosis: from basic mechanisms to clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Avasimibe, an ACAT inhibitor, enhances the lipid lowering effect of atorvastatin in subjects with homozygous familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Expression and regulation of hepatic drug and bile acid transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Role of CETP inhibitors in the treatment of dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Increasing high-density lipoprotein cholesterol in dyslipidemia by cholesteryl ester transfer protein inhibition: an update for clinicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Evaluation of lipoprotein(a) as a prothrombotic factor: progress from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Structural features of apolipoprotein B synthetic peptides that inhibit lipoprotein(a) assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Liver X receptor agonists inhibit tissue factor expression in macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Angiotensin II and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

The multiple actions of angiotensin II in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Induction of angiotensin converting enzyme and angiotensin II receptors in the atherosclerotic aorta of high-cholesterol fed Cynomolgus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Influence of the angiotensin converting enzyme inhibitor ramipril on high-sensitivity C-reactive protein (hs-CRP) in patients with documented atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

ACE inhibition lowers angiotensin II-induced chemokine expression by reduction of NF-kappaB activity and AT1 receptor expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Angiotensin-converting enzyme inhibition as antiatherosclerotic therapy: no answer yet. QUIET Investigators. QUinapril Ischemic Event Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Renin-angiotensin system as a therapeutic target in managing atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Acute and chronic angiotensin-1 receptor antagonism reverses endothelial dysfunction in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Comparison of the effects of losartan and atenolol on common carotid artery intima-media thickness in patients with hypertension: results of a 2-year, double-blind, randomized, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Irbesartan, an angiotensin type 1 receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Fluvastatin enhances the inhibitory effects of a selective angiotensin II type 1 receptor blocker, valsartan, on vascular neointimal formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Valsartan therapy has additive anti-oxidative effect to that of fluvastatin therapy against low-density lipoprotein oxidation: studies in hypercholesterolemic and hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Provision of cardiovascular protection by ACE inhibitors: a review of recent trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Should angiotensin II receptor blockers and statins be combined?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Challenges in improving prognosis and therapy: the Ongoing Telmisartan Alone and in Combination with Ramipril Global End point Trial programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Nitric oxide modulates the expression of monocyte chemoattractant protein 1 in cultured human endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Involvement of platelet cyclic GMP but not cyclic AMP suppression in leukocyte-dependent platelet adhesion to endothelial cells induced by platelet-activating factor in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Therapeutic potential of nitric oxide donors in the prevention and treatment of atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Production of hydroxyl radicals from the simultaneous generation of superoxide and nitric oxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

DNA damage induced by peroxynitrite: subsequent biological effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Role of phosphodiesterase 3 in NO/cGMP-mediated antiinflammatory effects in vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Systemic effects of S-nitroso-glutathione in the human following intravenous infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Cellular processes in atherogenesis: Potential targets of Ca2+ channel blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Future directions in the use of calcium antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Excess membrane cholesterol alters calcium movements, cytosolic calcium levels, and membrane fluidity in arterial smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Cholesterol, calcium and atherosclerosis: is there a role for calcium channel blockers in atheroprotection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Mechanisms of atherosclerotic plaque stabilization for a lipophilic calcium antagonist amlodipine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

The smooth muscle cell membrane during atherogenesis: a potential target for amlodipine in atheroprotection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Novel vascular biology of third-generation L-type calcium channel antagonists: ancillary actions of amlodipine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Unique atheroprotective property of azelnidipine, a dihydropyridine-based calcium antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Azelnidipine, a newly developed long-acting calcium antagonist, inhibits tumor necrosis factor-alpha-induced interleukin-8 expression in endothelial cells through its anti-oxidative properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Role of oxidative modifications in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Role of antioxidants in atherosclerosis: epidemiological and clinical update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Molecular action of vitamin E in lipoprotein oxidation: implications for atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Six-year effect of combined vitamin C and E supplementation on atherosclerotic progression: the Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Prevention of atherosclerotic progression in Watanabe rabbits by probucol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Clinical results with AGI-1067: a novel antioxidant vascular protectant

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Inflammation in atherosclerosis: new opportunities for drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Antiatherogenic effects of the antioxidant BO-653 in three different animal models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Characterization of the oxidation products of BO-653 formed during peroxyl radical-mediated oxidation of human plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Red wine consumption inhibits LDL oxidation and aggregation in humans and in atherosclerotic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Antiatherogenic potential of red wine: clinician update

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

LDL oxidation: therapeutic perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Inflammation, atherosclerosis, and coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Role of Monocytes in Atherogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Chemistry and pharmacology of vascular protectants: a novel approach to the treatment of atherosclerosis and coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Selective Inhibition of Endothelial and Monocyte Redox-Sensitive Genes by AGI-1067: A Novel Antioxidant and Anti-Inflammatory Agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

AGI-1067: a multifunctional phenolic antioxidant, lipid modulator, anti-inflammatory and antiatherosclerotic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Effects of AGI-1067 and probucol after percutaneous coronary interventions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Influenza and cardiovascular disease: a new opportunity for prevention and the need for further studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Flu vaccination in acute coronary syndromes and planned percutaneous coronary interventions (FLUVACS) Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Role of platelets in the pathophysiology of acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Role of antiplatelet drugs in the prevention of cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Aspirin and thrombinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Improved endothelial function by the thromboxane A2 receptor antagonist S 18886 in patients with coronary artery disease treated with aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

The role of the platelet glycoprotein IIb/IIIa in thrombosis and haemostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Platelet glycoprotein IIb/IIIa inhibitors: recognition of a two-edged sword?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Understanding thrombocytopenia and antigenicity with glycoprotein IIb-IIIa inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Platelets and anti-platelet therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

P2 receptors: new potential players in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Platelet ADP receptor antagonists: ticlopidine and clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

The thienopyridine derivatives (platelet adenosine diphosphate receptor antagonists), pharmacology and clinical developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

New therapeutic strategies with antiplatelet agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Resistance to clopidogrel: a review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Attenuation of the serotonin-induced increase in intracellular calcium in rat aortic smooth muscle cells by sarpogrelate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Sarpogrelate inhibits serotonin-induced proliferation of porcine coronary artery smooth muscle cells: implications for long-term graft patency

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Sarpogrelate HCl, a selective 5-HT2A antagonist, retards the progression of atherosclerosis through a novel mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Sarpogrelate treatment reduces restenosis after coronary stenting

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Thrombogenic and atherogenic activities of lysophosphatidic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Mechanisms of lysophosphatidic acid-induced DNA synthesis in vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Rapamycin in cardiovascular medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

ABT-578-eluting stents. The promising successor of sirolimus- and paclitaxel-eluting stent concepts?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Paclitaxel and cyclosporine A show supra-additive antiproliferative effects on smooth muscle cells by activation of protein kinase C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

PDGF receptor kinase inhibitors for the treatment of restenosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Aspirin in cardiovascular disorders. What is the optimum dose?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1582-4934.2005.TB00382.X

Antioxidant BO-653 and human macrophage-mediated LDL oxidation

21 January 2018

1 reference

12 December 2020

Inhibition of serotonin-induced vascular smooth muscle cell proliferation by sarpogrelate

1 reference

12 December 2020

New molecular targets for cholesterol-lowering therapy

1 reference

12 December 2020

Upregulation of LOX-1 expression in aorta of hypercholesterolemic rabbits: modulation by losartan

1 reference

12 December 2020

Pleiotropic effects of statins.

1 reference

12 December 2020

Regression by ACE inhibition of arteriosclerotic changes induced by chronic blockade of NO synthesis in rats

1 reference

12 December 2020

S17834, a new inhibitor of cell adhesion and atherosclerosis that targets nadph oxidase

1 reference

12 December 2020

Roles of angiotensin II type 2 receptor stimulation associated with selective angiotensin II type 1 receptor blockade with valsartan in the improvement of inflammation-induced vascular injury

1 reference

12 December 2020

The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: part I: oxidative stress and atherogenesis

1 reference

12 December 2020

Sarpogrelate, a specific 5HT2-receptor antagonist, improves the coronary microcirculation in coronary artery disease

1 reference

12 December 2020

The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: Part II: AT(1) receptor regulation

1 reference

12 December 2020

Ezetimibe. Schering-Plough.

1 reference

12 December 2020

Role of angiotensin II-regulated apoptosis through distinct AT1 and AT2 receptors in neointimal formation

1 reference

12 December 2020

Aspirin in the prophylaxis of coronary artery disease

1 reference

12 December 2020

Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes

1 reference

12 December 2020

Efficacy of glycoprotein IIb/IIIa-receptor inhibitors during percutaneous coronary intervention.

1 reference

12 December 2020

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report

1 reference

12 December 2020

Break the cycle: the role of cell-cycle modulation in the prevention of vasculoproliferative diseases

1 reference

12 December 2020

Modulating atherosclerosis through inhibition or blockade of angiotensin

1 reference

12 December 2020

Thrombus formation on ruptured atherosclerotic plaques and rethrombosis on evolving thrombi

1 reference

12 December 2020

Attenuation of changes in Gi‐proteins and adenylyl cyclase in heart failure by an ACE inhibitor, imidapril

1 reference

12 December 2020

Ezetimibe: a first-in-class, novel cholesterol absorption inhibitor.

1 reference

12 December 2020

Determinants of the cost-effectiveness of statins

1 reference

12 December 2020

Potential role of lysophosphatidic acid in hypertension and atherosclerosis.

1 reference

12 December 2020

Failure of aspirin to prevent atherothrombosis: potential mechanisms and implications for clinical practice

1 reference

12 December 2020

Therapeutic potentials of sarpogrelate in cardiovascular disease

1 reference

12 December 2020

Amlodipine and atorvastatin in atherosclerosis: a review of the potential of combination therapy

1 reference

12 December 2020

Renin-angiotensin system and atherosclerosis

1 reference

12 December 2020

Role of cholesterol in cardiovascular dysfunction

1 reference

12 December 2020

1 reference

12 December 2020

Differential gene expression in infarct scar and viable myocardium from rat heart following coronary ligation.

1 reference

12 December 2020

Losartan inhibited expression of matrix metalloproteinases in rat atherosclerotic lesions and angiotensin II-stimulated macrophages

1 reference

12 December 2020

Antioxidants and atherosclerosis: emerging drug therapies

1 reference

12 December 2020

Lp-PLA2 inhibitors (GlaxoSmithKline)

1 reference

12 December 2020

Platelet-derived serotonin, the endothelium, and cardiovascular disease

1 reference

12 December 2020

Cholesterol enrichment increases basal and agonist-stimulated calcium influx in rat vascular smooth muscle cells

1 reference

12 December 2020

1 reference

12 December 2020

Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit

1 reference

12 December 2020

Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells

1 reference

12 December 2020

The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium

1 reference

12 December 2020

Accelerated atherosclerosis in prolonged maintenance hemodialysis

1 reference

12 December 2020

Isoforms of nitric oxide synthase: functions in the cardiovascular system

1 reference

12 December 2020

Antiatherosclerotic effects of the angiotensin-converting enzyme inhibitors captopril and fosinopril in hypercholesterolemic minipigs

1 reference

12 December 2020

Atherosclerosis alters the composition, structure and function of arterial smooth muscle cell plasma membranes

1 reference

12 December 2020

Nitric Oxide Protects Against Leukocyte-Endothelium Interactions in the Early Stages of Hypercholesterolemia

1 reference

12 December 2020

Inhibition of macrophage-dependent low density lipoprotein oxidation by nitric-oxide donors

1 reference

12 December 2020

An update on coronary risk factors

1 reference

12 December 2020

The mechanism of anti-thrombotic, thrombolytic and fibrinolytic actions of camonagrel--a new thromboxane synthase inhibitor.

1 reference

12 December 2020

Inhibitors of angiotensin converting enzyme decrease early atherosclerosis in hyperlipidemic hamsters. Fosinopril reduces plasma cholesterol and captopril inhibits macrophage-foam cell accumulation independently of blood pressure and plasma lipids

1 reference

12 December 2020

Rapamycin-induced inhibition of p34cdc2 kinase activation is associated with G1/S-phase growth arrest in T lymphocytes

1 reference

12 December 2020

Effect of angiotension II on the expression of the early growth response gene c-fos and DNA synthesis in human vascular smooth muscle cells

1 reference

12 December 2020

Rapamycin inhibits vascular smooth muscle cell migration

1 reference

12 December 2020

Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets

1 reference

12 December 2020

Effect of the direct nitric oxide donors linsidomine and molsidomine on angiographic restenosis after coronary balloon angioplasty. The ACCORD Study. Angioplastic Coronaire Corvasal Diltiazem

1 reference

12 December 2020

Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study

1 reference

12 December 2020

Paradoxical enhancement of atherosclerosis by probucol treatment in apolipoprotein E-deficient mice

1 reference

12 December 2020

2,3-Dihydro-5-hydroxy-2,2-dipentyl-4,6-di-tert-butylbenzofuran: design and evaluation as a novel radical-scavenging antioxidant against lipid peroxidation

1 reference

12 December 2020

Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery

1 reference

12 December 2020

The effect of chronic treatment with NO donors during intimal thickening and fatty streak formation

1 reference

12 December 2020

Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tiro

1 reference

12 December 2020

The vascular biology of S-nitrosothiols, nitrosated derivatives of thiols

1 reference

12 December 2020

Physical effects of cholesterol on arterial smooth muscle membranes: evidence of immiscible cholesterol domains and alterations in bilayer width during atherogenesis

1 reference

12 December 2020

Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.

1 reference

12 December 2020

Antioxidant effects of nitric oxide and nitric oxide donor compounds on low-density lipoprotein oxidation

1 reference

12 December 2020

10.1111/J.1582-4934.2005.TB00382.X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6740287&resulttype=core&format=json

12 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6740287&resulttype=core&format=json

12 May 2020

PubMed publication ID

16364193

1 reference